BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
72.65
-0.15 (-0.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close72.80
Open73.33
Bid0.00 x 1200
Ask0.00 x 800
Day's Range72.28 - 74.49
52 Week Range70.82 - 106.74
Volume1,152,202
Avg. Volume1,118,074
Market Cap13.038B
Beta (3Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GuruFocus.com

    Stocks That Fell to 3-Year Lows in the Week of Sept. 13

    Altria Group Inc. (MO), BioMarin Pharmaceutical Inc. (BMRN), Pennant Park Investment Corp. (PNNT), and Rigel Pharmaceuticals Inc. (RIGL) have declined to their three-year lows Continue reading...

  • Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Overpaying Its CEO?
    Simply Wall St.

    Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Overpaying Its CEO?

    Jean-Jacques Bienaimé has been the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) since 2005. First, this article...

  • BioMarin (BMRN) Down 7.3% Since Last Earnings Report: Can It Rebound?
    Zacks

    BioMarin (BMRN) Down 7.3% Since Last Earnings Report: Can It Rebound?

    BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 31% Discount?
    Simply Wall St.

    Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 31% Discount?

    Does the August share price for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reflect what it's really worth? Today, we...

  • The $200K Club: NetApp's median employee gets a pay boost to join the salary ranks of Google, Netflix and Facebook
    American City Business Journals

    The $200K Club: NetApp's median employee gets a pay boost to join the salary ranks of Google, Netflix and Facebook

    NetApp Inc. this year paid its median employee just shy of $200,000 — a level that puts it on par with some of Silicon Valley's biggest companies and represents a 26 percent jump, year-over-year.

  • 6 Underperforming Stocks in Gurus' Portfolios
    GuruFocus.com

    6 Underperforming Stocks in Gurus' Portfolios

    Concho Resources makes the list Continue reading...

  • Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
    Zacks

    Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval

    Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year. The company plans expansion of gene therapy program into other indications including multiple sclerosis.

  • Thomson Reuters StreetEvents

    Edited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMT

    Q2 2019 Biomarin Pharmaceutical Inc Earnings Call

  • BioMarin's Roller Coaster Continues
    Motley Fool

    BioMarin's Roller Coaster Continues

    Long-term investors need to learn to stomach the ride.

  • Biomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call Transcript
    Motley Fool

    Biomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call Transcript

    BMRN earnings call for the period ending June 30, 2019.

  • BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss
    Zacks

    BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss

    BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.

  • Barrons.com

    BioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Aren’t Worried

    The company lost 21 cents a share, while analysts had expected a loss of 11 cents a share, according to FactSet.

  • BioMarin Pharmaceutical (BMRN) Lags Q2 Earnings and Revenue Estimates
    Zacks

    BioMarin Pharmaceutical (BMRN) Lags Q2 Earnings and Revenue Estimates

    BioMarin (BMRN) delivered earnings and revenue surprises of -47.06% and -5.63%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Zacks

    Rate Cut Wait Almost Over

    Rate Cut Wait Almost Over

  • What's in the Cards for Sarepta (SRPT) This Earnings Season?
    Zacks

    What's in the Cards for Sarepta (SRPT) This Earnings Season?

    Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive second-quarter sales.

  • BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks

    BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth

    BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order — and more
    American City Business Journals

    Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order — and more

    Myovant's plan to control heavy menstrual bleeding, how President Trump's executive order on kidney treatments could help a San Francisco company and more in our Health Care Digest.

  • Markit

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BMRN had net inflows of $7.05 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Motley Fool

    Shake-Up in Big Weed

    One of the marijuana industry’s pioneers was just ousted from Canopy Growth. What comes next?

  • BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To Profit
    Simply Wall St.

    BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shift From Loss To Profit

    BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN): BioMarin Pharmaceutical Inc., a biotechnology company, develops and...

  • JP Morgan: 2 Gene Therapy Stocks to Buy Now
    TipRanks

    JP Morgan: 2 Gene Therapy Stocks to Buy Now

    JP Morgan’s Cory Kasimov is making bullish bets on these two gene therapy stocks. This is an area with the potential to completely transform the healthcare landscape. It involves making changes to DNA to help treat, or potentially even cure, a disease. Although it is still early days, there are an estimated 10,000 diseases caused by a single mutation that can theoretically be corrected with a targeted gene therapy. These are known as monogenic diseases. “Though relatively rare, they affect millions of people worldwide” writes the World Health Organization, adding that in Canada monogenic diseases may account for up to 40% of the work of hospital based paediatric practice (Scriver, 1995).Here we take a closer look at two gene therapy stocks JP Morgan’s Kasimov believes is primed to outperform. Note that both these stocks also score a ‘Strong Buy’ consensus from top-performing analysts. That’s based on all the ratings received by each stock over the last three months. Let’s take a closer look now: BioMarin (BMRN)BioMarin is a world leader in developing innovative therapeutics for rare genetic diseases. “We believe BioMarin’s depth and breadth of orphan disease assets present a unique opportunity in biotech” cheers Kasimov. Indeed, the company has seven products on the market, and a growing product pipeline of multiple clinical and preclinical candidates. Excitingly, this includes valrox gene therapy for the treatment of Hemophilia A. This genetic disease is caused by the deficiency of clotting factor VIII. It is the most common type of hemophilia, with an estimated 90,000 patients in the territories where BioMarin operates.Currently the standard of care for severe hemophilia A patients is intravenous infusions three times a week. However many patients still experience spontaneous bleeding events- which can prove fatal. In contrast, gene therapy has the promise of delivering, in as little as a single administration, the missing gene needed to produce factor VIII. BioMarin has now revealed plans to submit valrox for regulatory approval in US/EU in 4Q19. Kasimov calls the news “an incremental positive that could serve to help firmly establish valrox in the commercial setting well ahead of any potential competitors.”He sees the stock as ‘undervalued’ at current levels and writes: “BMRN remains a high conviction long-term idea between its orphan-focused, diversified base business (>$1B in sales), growing commercial portfolio, and potentially disruptive late-stage pipeline.” Kasimov has a $133 price target on the stock (65% upside potential).In total, eleven top analysts have published buy ratings on the stock in the last three months. So no hold or sell ratings here. Meanwhile the $133 average analyst price target suggests sizable upside potential of 60% lies ahead. View BMRN Price Target & Analyst Ratings Detail Bluebird Bio (BLUE)Bluebird Bio is a clinical-stage company that, like BioMarin, is developing potentially transformative gene therapies for severe genetic and rare diseases. In particular, the company has just released updated results for LentiGlobin- a potential treatment and cure for sickle cell disease (SCD). Investors are keeping a close eye on the sickle cell opportunity, as this is a severe life-shortening blood disorder affecting around 110,000 patients in the US. Kasimov describes the latest results as ‘consistent’ and ‘incredibly profound’, adding that “the SCD data, in particular, reaffirms our prevailing view that… LentiGlobin is going to be exceedingly hard to beat by earlier-stage competition.” Bluebird expects filing and approval for LentiGlobin for SCD to take place in 2022.At the same time, it’s the company’s broad focus that really sets BLUE apart. “One particularly attractive yet underappreciated aspect of Bluebird is all the different technologies it has at its disposal”, says Kasimov. For BLUE that means using the right tools/ combinations to effectively design novel therapeutic- be it gene therapy, gene therapy, CAR T capabilities or even gene editing. For example, the company has also demonstrated encouraging initial data for bb2121, a CAR-T therapy for the potential treatment of multiple myeloma, that it is developing with Celgene (CELG). Net-net “We remain intrigued by an innovative company that has the potential to go 4-for-4 with its lead assets and has a multitude of tools in the shed (an anti-pure-play) to fuel the pipeline for a long time to come” says the analyst. He has a Street-high price target on BLUE of $195 (52% upside potential), and concludes: “In our opinion, BLUE is well positioned for long-term success.” Overall, top analysts agree with this upbeat outlook. Three out of four analysts rate the stock a ‘buy.’ We can also see that the $153 average analyst price target indicates upside potential of 19%.View BLUE Price Target & Analyst Ratings DetailView other top biotech stock ideas with the Top Analysts' Stocks tool

  • BioMarin (BMRN) to File for Hemophilia A Candidate in Q4
    Zacks

    BioMarin (BMRN) to File for Hemophilia A Candidate in Q4

    BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.

  • 3 Top Biotech Stocks to Buy in July
    Motley Fool

    3 Top Biotech Stocks to Buy in July

    Here's why this team of biotech experts are giddy about these stocks right now.

  • Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals
    Investor's Business Daily

    Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals

    Sangamo stock popped Monday after the biotech company unveiled promising results for its Pfizer-partnered gene therapy in hemophilia A treatment. Sangamo stock jumped as much as 16.9%.